| P50 | author | Arno de Wilde | Q56941002 |
| | Wiesje van der Flier | Q57525101 |
| | Femke Bouwman | Q88621754 |
| | Marieke M van Buchem | Q89063324 |
| | Philip Scheltens | Q22280357 |
| | Frederik Barkhof | Q42355589 |
| P2093 | author name string | Andrew Stephens | |
| | René H J Otten | |
| P2860 | cites work | NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. | Q52589491 |
| | [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology. | Q52836660 |
| | Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project | Q59843497 |
| | Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q24595802 |
| | Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results | Q27345258 |
| | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860749 |
| | The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 |
| | Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B | Q29012704 |
| | Alzheimer's disease: the amyloid cascade hypothesis | Q29547160 |
| | The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29547554 |
| | The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease | Q29614406 |
| | Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers | Q29620245 |
| | Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria | Q30458193 |
| | Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. | Q31063014 |
| | Communicating mild cognitive impairment diagnoses with and without amyloid imaging | Q33640373 |
| | Should we disclose amyloid imaging results to cognitively normal individuals? | Q34286140 |
| | Public perceptions of presymptomatic testing for Alzheimer disease | Q35206422 |
| | Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants | Q35595661 |
| | Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis | Q35800785 |
| | Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues | Q35838385 |
| | Injury markers predict time to dementia in subjects with MCI and amyloid pathology | Q36330912 |
| | Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials | Q36638757 |
| | A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure | Q36719734 |
| | Dementia specialists and early adoption of amyloid imaging | Q36806396 |
| | Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment | Q36883137 |
| | Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit | Q36885357 |
| | A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease | Q36926707 |
| | Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations | Q36929890 |
| | Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association | Q37069527 |
| | Disclosure of amyloid imaging results to research participants: has the time come? | Q37135140 |
| | Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. | Q37184248 |
| | Using AD biomarker research results for clinical care: a survey of ADNI investigators | Q37227059 |
| | Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review. | Q37406073 |
| | Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study | Q37524511 |
| | Use of amyloid PET across the spectrum of Alzheimer's disease: clinical utility and associated ethical issues | Q38219529 |
| | Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability. | Q38691914 |
| | Patient and caregiver reactions to clinical amyloid imaging. | Q39160016 |
| | Diagnostic dilemmas in Alzheimer's disease: Room for shared decision making | Q42655556 |
| | Clinicians' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project | Q42655628 |
| | Patients' and caregivers' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project | Q42655681 |
| | Alzheimer's disease drug development pipeline: 2017. | Q42655757 |
| | Study partners should be required in preclinical Alzheimer's disease trials. | Q46028917 |
| | Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context. | Q47115002 |
| | 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). | Q47209544 |
| | 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). | Q47209556 |
| | 18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). | Q47209563 |
| | Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults | Q47742387 |
| | Safety of disclosing amyloid status in cognitively normal older adults | Q47953945 |
| | Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study | Q48254703 |
| | Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study | Q48455136 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dementia | Q83030 |
| | positron emission tomography | Q208376 |
| | systematic review | Q1504425 |
| P304 | page(s) | 72 | |
| P577 | publication date | 2018-07-28 | |
| P1433 | published in | Alzheimers Research & Therapy | Q15716761 |
| P1476 | title | Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review | |
| P478 | volume | 10 | |